Surface-linked liposomal antigen induces ige-selective unresponsiveness regardless of the lipid components of liposomes.
We have previously reported that antigen coupled with liposomes induced antigen-specific and IgE-selective unresponsiveness in mice. This antigen preparation was investigated for application in a novel vaccine protocol to induce minimal IgE synthesis. In this study, ovalbumin (OVA)-liposome conjugates were made using liposomes of four different lipid components, including unsaturated carrier lipid and three different saturated carrier lipids, after which the induction of anti-OVA antibody production was investigated in mice. All of the OVA-liposome conjugates induced IgE-selective unresponsiveness. The membrane fluidity of liposomes, as measured by detecting changes in the fluorescence polarization of a 1,6-diphenyl-1,3,5-hexatriene (DPH) probe located in the bilayers, was significantly higher in liposomes consisting of unsaturated carrier lipids than those of the other liposomes consisting of saturated carrier lipids. The highest titer of anti-OVA IgG was observed in mice immunized with OVA-liposomes made using liposomes consisting of unsaturated carrier lipids. In addition, among these OVA-liposomes, the one possessing the longest carbon chain induced the lowest IgG antibody production. These results suggest that the membrane fluidity of liposomes might affect the adjuvant effect of liposomes but not the induction of IgE-selective unresponsiveness in immunizations with surface-linked liposomal antigens.
Nakano
Y
Y
NOF Corporation, Tsukuba Research Laboratory, Ibaraki, Japan.
Mori
M
M
Nishinohara
S
S
Takita
Y
Y
Naito
S
S
Kato
H
H
Taneichi
M
M
Komuro
K
K
Uchida
T
T
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology; D000818:Animals; D000906:Antibodies / Q000276:immunology; D000954:Antigens, Surface / Q000008:administration & dosage / Q000276:immunology*; D016207:Cytokines / Q000187:drug effects / Q000378:metabolism; D005260:Female; D007073:Immunoglobulin E / Q000276:immunology*; D007074:Immunoglobulin G / Q000276:immunology; D008055:Lipids / Q000737:chemistry / Q000494:pharmacology; D008081:Liposomes / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology; D008560:Membrane Fluidity; D051379:Mice; D008807:Mice, Inbred BALB C; D010047:Ovalbumin / Q000008:administration & dosage / Q000276:immunology; D013154:Spleen / Q000166:cytology / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D014612:Vaccines / Q000737:chemistry / Q000276:immunology / Q000494:pharmacology
D000276:Adjuvants, Immunologic; D000906:Antibodies; D000954:Antigens, Surface; D016207:Cytokines; D007074:Immunoglobulin G; D008055:Lipids; D008081:Liposomes; D014612:Vaccines; D007073:Immunoglobulin E; D010047:Ovalbumin